These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 1636234)
1. Carcinoma in situ. Lamm DL Urol Clin North Am; 1992 Aug; 19(3):499-508. PubMed ID: 1636234 [TBL] [Abstract][Full Text] [Related]
2. Carcinoma in situ and treatment options. Erton M; Ilker Y; Akdaş Int Urol Nephrol; 1996; 28(1):33-42. PubMed ID: 8738617 [TBL] [Abstract][Full Text] [Related]
3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
4. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
5. Principles of intravesical chemotherapy and immunotherapy. Sarosdy MF Urol Clin North Am; 1992 Aug; 19(3):509-19. PubMed ID: 1636235 [TBL] [Abstract][Full Text] [Related]
6. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Palou J; Xavier B; Laguna P; Montlleó M; Vicente J Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354 [TBL] [Abstract][Full Text] [Related]
7. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. Kim JC; Steinberg GD J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460 [TBL] [Abstract][Full Text] [Related]
8. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902 [TBL] [Abstract][Full Text] [Related]
9. When intravesical measures fail. Indications for cystectomy in superficial disease. Hudson MA Urol Clin North Am; 1992 Aug; 19(3):601-9. PubMed ID: 1636242 [TBL] [Abstract][Full Text] [Related]
10. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin. Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815 [TBL] [Abstract][Full Text] [Related]
11. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]